Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.

Abstract

BACKGROUND Upregulation of N-cadherin promotes dysregulated cell growth, motility, invasiveness, plus maintenance of vascular stability and is associated with cancer progression in several human tumour types. N-cadherin is expressed also on tumour cells and the anti-N-cadherin cyclic pentapeptide ADH-1, tested in the present study, can exert a direct antitumour effect. PATIENTS AND METHODS Adult patients with advanced solid malignancies expressing N-cadherin on tumour biopsies carried out in the previous 12 months received escalating i.v. doses of ADH-1 given weekly (initially for 3 of 4 weeks, then every week). Plasma pharmacokinetics (PK) was studied at cycle 1. Blood flow changes were assessed after first dosing in all patients treated in the initial regimen. RESULTS In all, 129 patients were screened, 65 (50%) were N-cadherin positive, and 30 were enrolled. The doses ranged from 150 to 2400 mg/m(2); no maximum tolerated dose was reached. Treatment was well tolerated with asthenia as the most frequent adverse event. Two patients with ovarian cancer showed prolonged disease stabilisation while one patient with fallopian tube carcinoma achieved a mixed response. PK was linear in the range of doses tested. CONCLUSION ADH-1 is the first anti-N-cadherin compound tested in humans. In N-cadherin-positive patients, ADH-1 showed an acceptable toxicity profile, linear PK and hints of antitumour activity in gynaecological cancers.

DOI: 10.1093/annonc/mdn695
0100200200920102011201220132014201520162017
Citations per Year

537 Citations

Semantic Scholar estimates that this publication has 537 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Perotti2009ClinicalAP, title={Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.}, author={Antonella Perotti and Cristiana Sessa and Alba Mancuso and Cristina Noberasco and Sara Cresta and Alberta Locatelli and Maria Luisa Carcangiu and Katia Passera and Antonio Braghetti and Davide Scaramuzza and Flavia Zanaboni and Angelica Fasolo and Giuseppe Capri and Monica Miani and W P Peters and Luca Gianni}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2009}, volume={20 4}, pages={741-5} }